Chairman Neal Statement on the Trump Administration’s Drug Pricing Executive Orders

Jul 24, 2020
Press Release
WASHINGTON, DC – Today, House Ways and Means Committee Chairman Richard E. Neal (D-MA) released the following statement after President Trump signed several drug pricing Executive Orders:
"Yet again, President Trump provides fanfare but no real policy action. Today's announcement won’t do anything to lower the high cost of medicines that Americans worry about around their kitchen tables. If he were serious about putting the needs of the American people first and lowering drug prices, he would tell the Senate to pass H.R. 3 and sign it into law. H.R. 3 is the comprehensive, House-passed legislation that would empower the HHS Secretary to negotiate prescription drug prices, saving nearly $500 billion in prescription drug costs for both Medicare beneficiaries and patients at-large. Instead of allowing negotiation, the President is once again siding with prescription drug corporations over the American people.
“The Ways and Means Committee has taken action to meaningfully lower prescription drug costs. Meanwhile, the President is trying to trick the American people into thinking he’s providing relief in an attempt to score political points.”
Read Ways and Means Committee Democrats’ 2019 report, “A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices,” HERE.